<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02263079</url>
  </required_header>
  <id_info>
    <org_study_id>NV25361</org_study_id>
    <secondary_id>2006-000977-31</secondary_id>
    <nct_id>NCT02263079</nct_id>
  </id_info>
  <brief_title>A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase</brief_title>
  <official_title>A Phase IIIb, Randomized, Open-Label Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Patients in Children With HBeAg Positive Chronic Hepatitis B in the Immune-Tolerant Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, controlled, parallel group, open-label multicenter study will evaluate the
      efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus
      lamivudine or entecavir compared with an untreated control group in participants with HBeAg
      positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2014</start_date>
  <completion_date type="Actual">January 29, 2020</completion_date>
  <primary_completion_date type="Actual">January 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation</measure>
    <time_frame>24 weeks post-end of treatment /end of untreated observation (Week 80)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Loss of HBsAg</measure>
    <time_frame>1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)</measure>
    <time_frame>24 weeks post-end of treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of anti-HBs</measure>
    <time_frame>24 weeks post-end of treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-Hbe), Defined as Loss of HBeAg and Presence of anti-Hbe</measure>
    <time_frame>24 weeks post-end of treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [&lt;] 20,000 International Units per Milliliter [IU/mL], &lt; 2000 IU/mL, or Undetectable HBV DNA)</measure>
    <time_frame>24 weeks post-end of treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HBV DNA Levels</measure>
    <time_frame>Baseline, 24 weeks post-end of treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of anti-HBe) and HBV DNA Levels &lt;20,000 IU/mL</measure>
    <time_frame>24 weeks post-end of treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of anti-HBe) and HBV DNA Levels &lt;2000 IU/mL</measure>
    <time_frame>24 weeks post-end of treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Adverse Events</measure>
    <time_frame>Baseline up to 1 year after end of treatment (End of Treatment = Week 56)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Pediatric Immuno-Tolerant Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Peg-IFN-Alfa-2A + Lamivudine or Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Control Participants</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated control participants will be observed up to 80 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).</description>
    <arm_group_label>Peg-IFN-Alfa-2A + Lamivudine or Entecavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).</description>
    <arm_group_label>Peg-IFN-Alfa-2A + Lamivudine or Entecavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon Alfa-2A</intervention_name>
    <description>Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m^2) BSA.</description>
    <arm_group_label>Peg-IFN-Alfa-2A + Lamivudine or Entecavir</arm_group_label>
    <other_name>Pegasys, Peg-IFN-Alfa-2A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive for HBsAg and HBeAg for more than 6 months prior to baseline

          -  Detectable HBV-DNA (&gt;20,000 IU/mL) as measured by polymerization chain reaction (PCR)
             or hybridization on at least 2 occasions at least one month apart with the latest
             determination obtained less than or equal to (&lt;/=) 42 days prior to baseline

          -  Compensated liver disease (Child-Pugh Class A clinical classification)

          -  Either Liver biopsy performed within 2 years prior to baseline showing no or minimal
             fibrosis (Liver Biopsy Scores and stable normal ALT levels (less than or equal to
             upper limit of normal [ULN]) during the 6 months leading up to baseline (including two
             separate occasions at least 1 month apart over the 6 months prior to baseline).
             Screening ALT levels must be normal (&lt;/= ULN) OR Stable normal ALT levels (&lt;/= ULN),
             during the 1 year leading up to baseline (including three separate occasions at least
             1 month apart over the 1 year prior to baseline) and no signs of hepatocellular
             carcinoma (HCC), advanced fibrosis/cirrhosis, or splenomegaly on liver abdominal
             ultrasound at screening. Screening ALT levels must be normal (&lt;/= ULN)

        Exclusion Criteria:

          -  Participants who have received investigational drugs or licensed treatments with anti
             HBV activity (Exception: Participants who have had a limited [&lt;/= 7-day] course of
             acyclovir for herpetic lesions more than 1 month before the study baseline visit are
             not excluded)

          -  Participants who have participated in any other clinical trial or who have received
             any investigational drug within 6 months prior to baseline

          -  Known hypersensitivity to interferon (IFN), pegylated interferon-alfa-2a or lamivudine
             or entecavir

          -  Positive test results at screening for hepatitis A virus Immunoglobulin M (IgM)
             antibody (Ab), anti-hepatitis C virus (HCV) Ab, anti- hepatitis D (HDV) Ab or
             anti-human immunodeficiency virus (HIV) Ab

          -  Decompensated liver disease (e.g., Child-Pugh Class B or C clinical classification or
             clinical evidence such as ascites or varices)

          -  Advanced fibrosis or cirrhosis

          -  Suspicion of HCC on liver abdominal ultrasound (all patients to have liver abdominal
             ultrasound within 6 months prior to baseline)

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than CHB including metabolic liver diseases such as hemochromatosis, Wilson's
             disease or alpha-1 anti-trypsin deficiency

          -  Active substance abuse within 6 months prior to screening

          -  Sexually active females of childbearing potential and sexually active males who are
             not willing to utilize reliable contraception during treatment and for 90 days
             following the end of treatment

          -  Females who are pregnant or who are breastfeeding (females of childbearing potential
             who have a positive urine or serum pregnancy test result within 24 hours of baseline
             are excluded)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Mercy Hosp Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Womens and Childrens Hospital; Department of Gastroenterology</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kinder- und Jugendmedizin</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunerschen Kinderspital, Kinderchirurgische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Wuppertal, Zentrum für Kinder- und Jugendmedizin, Universität Witten-Herdecke</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; U.O. Malattie Infettive</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Center; Department of Paediatrics</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grigore Alexandrescu Emergency Clinical Hospital for Children</name>
      <address>
        <city>Bucharest</city>
        <zip>011743</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSI Scientific research Institute of children's infections</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Gepatolog</name>
      <address>
        <city>Samara</city>
        <zip>443100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital-Linkou; Division of Pediatric Gastroenterology, Dept Pediatrics</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University Medical School Department of Pediatrics; Pediatric Infectious Diseases</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University School of Medicine, Pediatrics Department; Pediatric Gastroenterology</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Uni , School of Medicine; Gastroenterology</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi Universitesi Tip Fakultesi Pediyatri Anabilim Dalı; Pediyatrik Gastroenteroloji</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute of the pediatrics, obstetrics and gynecology</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children'S Hopsital; Liver Unit</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Dominican Republic</country>
    <country>Egypt</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 15, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

